- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
FDA approves Dysport for cosmetic, therapeutic uses
International report ? The Food and Drug Administration (FDA) approved the Biologics License Application for Dysport (botulinum toxin type A, Medicis, Ipsen) for the treatment of both cervical dystonia in adults and to temporarily improve the appearance of moderate-to-severe glabellar lines in adults younger than 65, Globe Newswire reports.
International report
- The Food and Drug Administration (FDA) approved the Biologics License Application for Dysport (botulinum toxin type A, Medicis, Ipsen) for the treatment of cervical dystonia in adults and to temporarily improve the appearance of moderate-to-severe glabellar lines in adults younger than 65, Globe Newswire reports.
Reloxin, which was the proposed name for Ipsen’s U.S. botulinum toxin product indicated for cosmetic use, will now be marketed under the Dysport name. Ipsen will market the toxin for the therapeutic use and Medicis will market Dysport for the aesthetic indication.
Dysport has established a separate name from other marketed botulinum toxin products, abobotulinumtoxinA, according to Globe Newswire.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
